Adamas Pharmaceuticals Inc Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Revenues:
Product sales, net
Product sales
License and grant revenue
Royalty revenue
Total revenues

Costs and operating expenses:
Cost of product sales
Research and development
General and administrative, net
Selling, general and administrative, net
Total costs and operating expenses

Loss from operations
Interest and other income, net
Interest expense
Loss before income taxes
Benefit for income taxes
Net loss
Basic
Diluted
Basic (in dollars per share)
Diluted (in dollars per share)
Basic (in shares)
Diluted (in shares)
Net loss per share, basic and diluted (in dollars per share)
Weighted average shares used in computing net loss per share, basic and diluted (in shares)

Comments